Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.48 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.46 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.42 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.42 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11259848 | 0.99 | HTR1A (0.49) | HTR1ATMEM97SIGMAR1ADRA1DADRA1A | |
| SCHEMBL10807843 | 0.90 | GAA (0.49) | HTR1ATMEM97SIGMAR1ADRA1DADRA1A | |
| SCHEMBL27721335 | 0.80 | GRIN1 (0.44) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL30904664 | 0.80 | HTR1A (0.67) | HTR1ATMEM97SIGMAR1ADRA1DADRA1A | |
| Oxapium SCHEMBL24857 | 0.74 | CTDSP1 (0.47) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| Oxapium SCHEMBL1316687 | 0.73 | CTDSP1 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10807846 | 0.71 | CHRM2 (0.39) | HTR1AADRA1AADRA2CGRIN1GRIN2A | |
| SCHEMBL14039627 | 0.70 | CHRM2 (0.43) | GRIN1GRIN2ACHRM2CHRM4CHRM5 | |
| SCHEMBL10759760 | 0.70 | TMEM97 (0.49) | HTR1ATMEM97SIGMAR1ADRA1DADRA1A | |
| SCHEMBL28143108 | 0.68 | CHRM2 (0.38) | SIGMAR1GRIN1GRIN2ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029183-A | Recombinant AAV with improved tropism and specificity | 艾菲尼亚治疗公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4713345-A2 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260062450-A1 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | AFFINIA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | claimed |
| WO-2025227063-A1 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4605410-A1 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4573203-A2 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2025-06-25 | — | — | EP | claimed |
| WO-2024238807-A2 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2024086747-A1 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2024-04-25 | — | — | WO | claimed |
| US-20240115734-A1 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. | 2024-04-11 | — | — | US | claimed |
| WO-2024040193-A2 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2024-02-22 | — | — | WO | claimed |
| US-20230331782-A1 | Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease | UNIV PENNSYLVANIA (US) | 2023-10-19 | — | — | US | claimed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | claimed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | claimed |
| US-20230142780-A1 | USE OF VIRAL VECTORS FOR CORONAVIRUS VACCINE PRODUCTION | 4MVAC LLC (US) | 2023-05-11 | — | — | US | claimed |
| EP-4171659-A2 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | Lycia Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | claimed |
| EP-4171658-A2 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | Lycia Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | claimed |
| US-20220411820-A1 | METHODS AND COMPOSITIONS FOR MODULATING THE INTERACTION BETWEEN ADENO-ASSOCIATED VIRUS (AAV) AND THE AAV RECEPTOR (AAVR) FOR ALTERED BIO-DISTRIBUTION OF AAV | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022173847-A2 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | Affinia Therapeutics Inc. (US) | 2022-08-18 | — | — | WO | claimed |
| WO-2022150634-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE INTERACTION BETWEEN ADENO-ASSOCIATED VIRUS (AAV) AND THE AAV RECEPTOR (AAVR) FOR ALTERED BIO-DISTRIBUTION OF AAV | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-07-14 | — | — | WO | claimed |
| EP-3969061-A1 | METHODS OF REDOSING GENE THERAPY VECTORS | BioMarin Pharmaceutical Inc. (US) | 2022-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | HTR1A 4594/4885SIGMAR1 2866/4885ADRA1D 4624/4885 |
| US-20260062450-A1 | RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY | VSIG8, NRP1, ITGAV | HTR1A 3686/4885SIGMAR1 1710/4885ADRA1D 716/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | HTR1A 4079/4885SIGMAR1 1616/4885ADRA1D 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.